



If your FGFR2-positive bile duct cancer has progressed on chemotherapy

It's time to consider a personalized approach

Ask your healthcare provider if TRUSELTIQ may be the right treatment option for you.

FGFR2=fibroblast growth factor receptor².

What is TRUSELTIQ?

TRUSELTIQ is a prescription medicine used to treat adults with bile duct cancer (cholangiocarcinoma) that has spread or cannot be removed by surgery, who have already received a previous treatment, and whose tumor has a certain type of abnormal "FGFR2" gene. Your healthcare provider will test your cancer for certain FGFR2 gene abnormalities and make sure that TRUSELTIQ is right for you.

TRUSELTIQ is approved based on tumor response and duration of response. Data are not yet available to show if TRUSELTIQ improves symptoms or survival.

IMPORTANT SAFETY INFORMATION

What are the possible side effects of TRUSELTIQ?

Serious side effects of TRUSELTIQ include:

- **Eye problems:** Certain eye problems are common with TRUSELTIQ but can also be serious. Eye problems include dry or inflamed eyes, inflamed cornea (front part of the eye), increased tears, and disorders of the retina (an internal part of the eye). You will need to see an eye specialist for a complete eye exam before you start treatment with TRUSELTIQ, at 1 month, at 3 months, and then every 3 months during treatment with TRUSELTIQ. Your healthcare provider should closely monitor you for eye problems
 - You should use artificial tear substitutes, or hydrating or lubricating eye gels as needed, to help prevent or treat dry eyes
 - **Tell your healthcare provider right away** if you develop any changes in your vision, including blurred vision, during treatment with TRUSELTIQ. You may need to see an eye specialist right away

Please see Important Safety Information throughout and accompanying full Prescribing Information, including Patient Information.

Not an actual patient.



You and your healthcare provider have decided that TRUSELTIQ is the next step for you on your journey to treat your bile duct cancer.

TRUSELTIQ is for people who:

- Have a certain type of abnormal gene to the FGFR2 protein
- Have cancer that has spread or that cannot be surgically removed
- Have already been treated for bile duct cancer

How does TRUSELTIQ work?

In people who have FGFR2 fusion-driven bile duct cancer, bile duct cells create an abnormal version of the FGFR2 protein. This abnormal protein causes cells to grow and divide out of control, leading to cancerous tumors. TRUSELTIQ blocks the rapid growth of FGFR2 fusion-driven cancer cells.



What to tell your healthcare provider

Tell your healthcare provider:

- About all the medicines you're currently taking (including prescription medicines, over-the-counter medicines, vitamins, and herbal supplements)
- If you have vision or eye problems, kidney problems, liver problems, are pregnant, or plan to become pregnant

During treatment with TRUSELTIQ you should not:

- Become pregnant as it may harm your unborn baby or cause loss of your pregnancy (miscarriage)
- Eat or drink grapefruit products

IMPORTANT SAFETY INFORMATION

What are the possible side effects of TRUSELTIQ™ (infigratinib)? (cont)

Serious side effects of TRUSELTIQ include:

- **High phosphate levels in the blood (hyperphosphatemia) and buildup of minerals in different tissues in your body:** Hyperphosphatemia is common with TRUSELTIQ but can also be serious and may lead to a buildup of minerals such as calcium in different tissues in your body. Your healthcare provider will check your blood phosphate levels during treatment with TRUSELTIQ
 - Your healthcare provider may prescribe phosphate-lowering therapy or change, interrupt, or stop TRUSELTIQ if needed
 - **Tell your healthcare provider right away** if you develop any muscle cramps, numbness, or tingling around your mouth

The most common side effects of TRUSELTIQ include changes in kidney function blood tests; decreased phosphate, sodium, potassium, and protein (albumin) in the blood; separation of nails from the bed or poor formation of the nail; mouth sores; changes in liver function blood tests; decreased red blood cell, white blood cell, and platelet counts; increased lipase, calcium, fat (triglycerides), and uric acid in the blood; dry eyes; feeling tired or weak; hair loss; redness, swelling, peeling or tenderness on the hands or feet ("hand-foot" syndrome); joint pain; changes in sense of taste; constipation; stomach-area (abdominal) pain or discomfort; dry mouth; eyelash changes; diarrhea; dry skin; decreased appetite; blurred vision; and vomiting.

These are not all the possible side effects of TRUSELTIQ. For more information, talk to your healthcare provider or pharmacist. You may report side effects to FDA at 1-800-FDA-1088.

What should I tell my healthcare provider before taking TRUSELTIQ?

- **All your medical conditions**, including vision or eye, kidney, or liver problems
- **All the medicines you take**, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take medicines used to decrease stomach acid and treat heartburn, called proton pump inhibitors (PPIs), H2 blockers, or antacids. You should avoid taking these medicines during treatment with TRUSELTIQ. If you cannot avoid taking H2 blockers, take TRUSELTIQ 2 hours before or 10 hours after taking the H2 blocker. If you cannot avoid taking antacids, take TRUSELTIQ 2 hours before or 2 hours after taking the antacid
- **If you are pregnant or plan to become pregnant.** TRUSELTIQ can harm your unborn baby. Females who can become pregnant should have a pregnancy test before starting treatment with TRUSELTIQ and use effective birth control during treatment with TRUSELTIQ and for 1 month after the final dose. Talk to your healthcare provider about birth control methods. Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with TRUSELTIQ. Males with female partners who can become pregnant should use effective birth control during treatment with TRUSELTIQ and for 1 month after the final dose
- **If you are breastfeeding or plan to breastfeed.** Do not breastfeed while taking TRUSELTIQ and for 1 month after the final dose

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.FDA.gov/medwatch, or call 1-800-FDA-1088.

Please see Important Safety Information throughout and accompanying full Prescribing Information, including Patient Information.



You and your healthcare provider have decided that TRUSELTIQ is the next step for you on your journey to treat your bile duct cancer.

TRUSELTIQ is for people who:

- Have a certain type of abnormal gene to the FGFR2 protein
- Have cancer that has spread or that cannot be surgically removed
- Have already been treated for bile duct cancer

How does TRUSELTIQ work?

In people who have FGFR2 fusion-driven bile duct cancer, bile duct cells create an abnormal version of the FGFR2 protein. This abnormal protein causes cells to grow and divide out of control, leading to cancerous tumors. TRUSELTIQ blocks the rapid growth of FGFR2 fusion-driven cancer cells.



What to tell your healthcare provider

Tell your healthcare provider:


- About all the medicines you're currently taking (including prescription medicines, over-the-counter medicines, vitamins, and herbal supplements)
- If you have vision or eye problems, kidney problems, liver problems, are pregnant, or plan to become pregnant

During treatment with TRUSELTIQ you should not:

- Become pregnant as it may harm your unborn baby or cause loss of your pregnancy (miscarriage)
- Eat or drink grapefruit products



What you need to know about TRUSELTIQ dosing



Getting started on TRUSELTIQ

TRUSELTIQ is taken on a 28-day cycle

When you start, you will take TRUSELTIQ oral capsules daily for 21 days, followed by 7 days when you don't take any capsules. You will then repeat this process again each month.

TRUSELTIQ capsules should be:

- Taken once a day by mouth
- Taken on an empty stomach at least 1 hour before or 2 hours after a meal
- Taken at the same time every day
- Swallowed whole with a glass of water—no chewing or crushing the tablets



Your healthcare provider will watch your progress on TRUSELTIQ to see if you need a different dose schedule and to decide how long you should take it.

To learn more about TRUSELTIQ dosing, visit [TRUSELTIQ.com](https://www.truseltiq.com).

IMPORTANT SAFETY INFORMATION

What are the possible side effects of TRUSELTIQ? (cont)

The most common side effects of TRUSELTIQ include changes in kidney function blood tests; decreased phosphate, sodium, potassium, and protein (albumin) in the blood; separation of nails from the bed or poor formation of the nail; mouth sores; changes in liver function blood tests; decreased red blood cell, white blood cell, and platelet counts; increased lipase, calcium, fat (triglycerides), and uric acid in the blood; dry eyes; feeling tired or weak; hair loss; redness, swelling, peeling or tenderness on the hands or feet ("hand-foot" syndrome); joint pain; changes in sense of taste; constipation; stomach-area (abdominal) pain or discomfort; dry mouth; eyelash changes; diarrhea; dry skin; decreased appetite; blurred vision; and vomiting.

These are not all the possible side effects of TRUSELTIQ. For more information, talk to your healthcare provider or pharmacist. You may report side effects to FDA at 1-800-FDA-1088.

Please see Important Safety Information throughout and accompanying full Prescribing Information, including Patient Information.

Potential side effects you should be aware of with TRUSELTIQ

Understanding side effects

The information below will help you understand more about the possible side effects associated with TRUSELTIQ. However, please note that this is not a full list of side effects, and side effects not listed here may also occur. A full list of side effects can be found in the enclosed Prescribing Information.

Your healthcare provider will closely monitor your side effects throughout treatment using lab tests and other exams. If you experience any of the side effects below, or if you encounter other changes to your body that are different from how you normally feel, be sure to tell your healthcare provider. Your healthcare provider will evaluate your treatment plan and make any changes if needed.

Changes in blood tests

- Changes in kidney function
- Decreased levels of phosphate, sodium, and potassium
- Changes in liver function
- Decreased red blood cell, white blood cell, and platelet counts
- Increased lipase levels (done to check your pancreas)
- Increased calcium levels
- Increased fat levels (triglycerides)
- Increased levels of uric acid
- Decreased protein levels (albumin)

Changes to the nails, skin, or hair

- Nails separate from the bed or poor formation of the nail
- Hair loss
- Redness, swelling, peeling, or tenderness, mainly on the hands or feet ("hand-foot syndrome")
- Dry skin

Mouth symptoms

- Mouth sores
- Changes in sense of taste
- Dry mouth

Eye symptoms

- Dry eyes
- Changes in eyelashes
- Blurred vision

Stomach, digestion, and gastrointestinal symptoms

- Constipation
- Stomach-area (abdominal) pain or discomfort
- Diarrhea
- Decreased appetite
- Vomiting

Other

- Feeling tired or weak
- Joint pain

If you have questions about treatment with TRUSELTIQ, be sure to talk to your healthcare provider. You can also visit [TRUSELTIQ.com](https://www.truseltiq.com) to learn more.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.FDA.gov/medwatch](https://www.fda.gov/medwatch), or call 1-800-FDA-1088.



The ForgingBridges | TRUSELTIQ Access and Support program

We are pleased to provide a support program dedicated to helping you throughout your journey with TRUSELTIQ. For more information about ForgingBridges | TRUSELTIQ and how it can help you:

 **Call 1-888-55BRIDGE (1-888-552-7434) Monday-Friday, 8 AM-8 PM ET**  **Visit [TRUSELTIQ.com/forgingbridges](https://www.truseltiq.com/forgingbridges)**

Please see Important Safety Information throughout and accompanying full Prescribing Information, including Patient Information.



TRUSELTIQ.com

TRUSELTIQ™ is manufactured by QED Therapeutics, Inc.
TRUSELTIQ™ is a trademark of QED Therapeutics and co-marketed in the U.S. by Helsinn Therapeutics (U.S.), Inc. and QED Therapeutics. ForgingBridges is a trademark of BridgeBio.
QED Therapeutics is a member of the BridgeBio family.
©2021 Helsinn Healthcare SA. All rights reserved. Helsinn Group
©2021 QED Therapeutics, Inc. All rights reserved. US-INFC-2100011 09/21

